Research Analysts Offer Predictions for IRWD FY2024 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Investment analysts at Zacks Research reduced their FY2024 EPS estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Thursday, November 28th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.08 for the year, down from their prior forecast of $0.14. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.17 EPS and Q3 2026 earnings at $0.13 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business’s revenue was down 19.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 earnings per share.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Craig Hallum decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Trading Down 2.2 %

IRWD opened at $3.54 on Monday. The stock has a market capitalization of $566.51 million, a P/E ratio of -118.00 and a beta of 0.41. The stock has a 50-day moving average price of $4.10 and a 200-day moving average price of $5.14. Ironwood Pharmaceuticals has a 12-month low of $3.26 and a 12-month high of $15.70.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at $78,000. Vestcor Inc grew its holdings in Ironwood Pharmaceuticals by 37.8% during the third quarter. Vestcor Inc now owns 159,466 shares of the biotechnology company’s stock valued at $657,000 after purchasing an additional 43,703 shares during the period. Jane Street Group LLC increased its position in Ironwood Pharmaceuticals by 102.7% in the third quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company’s stock worth $1,333,000 after buying an additional 164,006 shares in the last quarter. Wolverine Trading LLC bought a new position in shares of Ironwood Pharmaceuticals in the third quarter worth about $51,000. Finally, Weiss Asset Management LP purchased a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $893,000.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 12.90% of the stock is currently owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.